市 场 研 究 [Table_Title] 万联晨会 [Table_MeetReportDate] 2025 年 07 月 01 日 星期二 [Table_Summary] 概览 核心观点 【市场回顾】 周一 A 股三大指数集体收涨，截止收盘，沪指收涨 0.59%，深成指收 涨 0.83%，创业板指收涨 1.35%。沪深两市成交额 14866.37 亿元。申 万行业方面，国防军工、传媒、通信领涨，非银金融、银行、交通运 输领跌；概念板块方面，兵装重组概念、脑机接口、光刻机涨幅居前， 期货概念、金属锌、乳业跌幅居前。港股方面，恒生指数收跌 0.87%， 恒生科技指数收跌 0.72%；海外方面，美国三大指数集体收涨，道指 收涨 0.63%，标普 500 收涨 0.52%，纳指收涨 0.47%。 【重要新闻】 【6 月份，我国制造业、非制造业和综合 PMI 分别为 49.7%、50.5%和 50.7%】国家统计局公布，6 月份，我国制造业、非制造业和综合 PMI 分别为 49.7%、50.5%和 50.7%，比上月上升 0.2、0.2 和 0.3 个百分 点，三大指数均有所回升。装备制造业、高技术制造业和消费品行业 ...

证券研究报告 2025 年 07 月 01 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3444.43 | 0.59 | | 深证成指 | 10465.12 | 0.83 | | 创业板指 | 2153.01 | 1.35 | | 科创 50 | 1003.41 | 1.54 | | 北证 50 | 1447.18 | 0.52 | | 沪深 300 | 3936.08 | 0.37 | A 股市场概览 | 类别 | 总市值 | 流通市 | 市盈率 | 市净率 | | --- | --- | --- | --- | --- | | | (亿元) | 值(亿元) | PE | PB | | 上证指数 | 668373 | 518986 | 12.31 | 1.28 | | 深证成指 | 229186 | 187895 | 20.34 | 2.15 | | 创业板指 | 60402 | 47793 | 28.11 | 3.92 | | 科创 50 | 35038 | 23365 | 54.71 | 4.21 | | 北证 50 | ...

重要的消息有哪些 7月1日（周二）申购提示 新股方面，同宇新材申购代码301630，发行价84.00元/股，申购上限1万股。 投资有风险，申购需谨慎。 1．6月30日，外交部发言人毛宁主持例行记者会。有记者就有外媒报道称，中美俄将共同纪念中国人民抗日战争暨世界反法西斯战争胜利80周年相关问题提问。对 此，毛宁表示，在上周举行的国新办的记者会上，有关部门介绍了抗战胜利80周年纪念活动邀请外国领导人的安排，你可以查阅。你提到的具体问题，目前没有可 以提供的信息。 2．商务部新闻发言人就加拿大政府关闭海康威视在加业务事答记者问。加方以"国家安全"为由，强行关闭海康威视在加业务，并禁止加政府部门购买或使用海康威 视产品。中方对此强烈不满、坚决反对。 3．6月30日，深交所发布《深圳证券交易所股票发行上市审核业务指引第8号——轻资产、高研发投入认定标准》（以下简称《指引》），自发布之日起施行。指 引根据创业板上市公司成长性、创新性特点明确了创业板"轻资产、高研发投入"的认定标准，有助于创业板更好服务科技创新和新质生产力发展。 4．财政部、税务总局、商务部发布关于境外投资者以分配利润直接投资税收抵免政策的公告，境外投资者 ...

证券研究报告 2025 年 7 月 1 日 星期二 【A 股市场大势研判】 板块排名： | 申万一级涨幅前五 | | | 申万一级跌幅前五 | 热点板块 n | 涨幅前五 | 热点板块跌幅前五 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 国防军工 | 4.35% | 非银金融 | -0.77% | 兵装重组概念 | 8.89% | 期货概念 | -0.44% | | 传媒 | 2.82% | 银行 | -0.34% | 脑机接口 | 5.17% | 金属锌 | -0.08% | | 通信 | 1.90% | 交通运输 | -0.09% | 光刻机 | 3.90% | 乳业 | -0.06% | | 电子 | 1.44% | 综合 | 0.06% | 成飞概念 | 3.82% | 盐湖提锂 | 0.01% | | 纺织服饰 | 1.41% | 石油石化 | 0.11% | 国产航母 | 3.68% | 水泥概念 | 0.01% | 资料来源：东莞证券研究所，iFinD 数据 后市展望： 三大指数上半年全线上涨收官 市场表现： | 指数名称 | ...

Group 1 - A-shares market showed strong performance with all major indices rising, including Shanghai Composite Index up 0.59%, Shenzhen Component Index up 0.83%, and ChiNext Index up 1.35% on the last trading day of June [1][2][7] - The total market turnover reached 15,172 billion, with over 4,000 stocks rising, indicating a broad-based rally [1][7] - In the first half of the year, small and mid-cap stocks outperformed, with over 3,700 stocks rising, and several sectors like AI models and new consumption gaining significant attention from investors [1][7] Group 2 - The military, pharmaceutical, and photovoltaic sectors led the gains on the last trading day of June, with notable stocks like Changcheng Military Industry and Huaren Health showing significant price movements [2][3] - The white wine sector experienced a notable surge, with stocks like JiuGuiJiu and SheDeJiuYe rising by 6.88% and 3.48% respectively, reflecting renewed investor interest [4][3] - The brain-computer interface sector also saw active trading, with a 5.17% increase in the sector, driven by developments from Neuralink and its ongoing clinical trials [5][6] Group 3 - The first half of 2023 saw major indices like the North Star 50 Index rising by 39.45%, indicating a strong market recovery [7] - Key sectors that attracted investment included AI models, humanoid robots, new consumption, innovative drugs, and solid-state batteries, with significant gains observed across these areas [7][8] - Structural opportunities are expected to dominate the upcoming earnings season, with a shift in active funds from pharmaceuticals and consumption towards technology and finance sectors [8]

Core Viewpoint - The stock of Jihua Group has experienced significant price fluctuations, with a cumulative deviation of 20% over three consecutive trading days, prompting the company to clarify its business operations and address media speculation regarding its involvement in the brain-computer interface sector [1][2]. Group 1: Stock Trading Anomalies - Jihua Group's stock price increased significantly on June 26, 27, and 30, 2025, with a cumulative price deviation of 20%, which is classified as abnormal trading activity according to Shanghai Stock Exchange regulations [1]. - The company has confirmed that there are no undisclosed significant events that could affect its stock price, following a thorough internal review and verification with its controlling shareholder [2]. Group 2: Business Operations - The company reported that its current business operations are normal, and there have been no significant changes in the internal or external operating environment [2]. - Jihua Group's main business includes the research, production, and sales of workwear, safety shoes, textile dyeing, and protective equipment, with no involvement in the brain-computer interface field as suggested by some media [2]. Group 3: Financial Performance - In the fiscal year, Jihua Group achieved a revenue of approximately 9.89 billion yuan, reflecting a year-on-year decrease of 14.49%, and reported a net loss attributable to shareholders of approximately 4.23 billion yuan, a significant decline compared to the previous year [3].

Core Insights - Neuralink has achieved a significant milestone with the ability to implant electrodes in the brain at a speed of 1.5 seconds per electrode, showcasing advancements in brain-machine interface (BMI) technology [26][66]. - The company has outlined an ambitious three-year roadmap aiming to restore vision to the blind by 2026 and integrate human consciousness with AI by 2028 [26][64]. - Seven volunteers have successfully used the Neuralink device to control games and robotic arms through thought, demonstrating the practical applications of this technology [28][34]. Group 1: Shenzhen's Breakthrough in Brain-Machine Interface - Shenzhen Second People's Hospital has successfully completed the first real-time decoding surgery in South China using high-density flexible film electrodes, marking a significant advancement in BMI technology [2][5]. - The surgery involved a 40-year-old patient with a brain vascular malformation, utilizing a 128-channel flexible electrode to achieve 97% accuracy in motion intention decoding with a 60-millisecond latency [2][10]. - This achievement represents a full cycle of "research-manufacturing-clinical validation" in Shenzhen's BMI technology, showcasing local innovation and collaboration [5][20]. Group 2: Clinical Application and Innovation - The high-density film electrodes developed by a local company, MicroLing Medical, are only 0.01 mm thick and provide excellent flexibility and biocompatibility, significantly improving signal acquisition quality [2][12]. - The establishment of the "Brain-Machine Interface Clinical Evaluation and Transformation Center" at Shenzhen Second People's Hospital aims to accelerate the clinical application of BMI technology, integrating research and clinical practice [22][24]. - The center will focus on standardizing data collection and management throughout the entire process from pre-operative assessment to post-operative rehabilitation, creating a closed-loop transformation path [24][22]. Group 3: Future Directions and Industry Impact - The successful application of BMI technology in Shenzhen is expected to serve as a model for the integration of medical and engineering resources, promoting innovation in treating neurological diseases [18][19]. - The collaboration between Shenzhen Second People's Hospital and MicroLing Medical exemplifies the synergy between academia, industry, and healthcare, aiming to enhance the clinical translation of advanced technologies [4][16]. - The advancements in BMI technology not only promise to improve patient outcomes but also position Shenzhen as a leader in the global neurotechnology landscape [20][19].

Core Insights - The brain-computer interface (BCI) sector is experiencing significant advancements, with both domestic and international developments highlighting its potential [1][2][3] Industry Development - The BCI technology is a crucial intersection of neuroscience and brain-like computing, categorized into invasive, semi-invasive, and non-invasive types based on signal acquisition and output methods [2] - The market size for BCIs in China is projected to reach 3.2 billion yuan in 2024, exceeding 5.5 billion yuan by 2027; globally, the medical application market for BCIs is expected to reach between 40 billion to 145 billion USD from 2030 to 2040 [2] - Various local governments in China are actively promoting BCI industry development, with plans to establish a robust ecosystem by 2030, including breakthroughs in foundational research and technology [2][3] Company Initiatives - Companies in China are leading in the development of intelligent BCI systems, with "Beijing Brain No. 1" and "Beijing Brain No. 2" systems currently in clinical validation stages [4] - Sanbo Brain Hospital recently completed a successful trial using an invasive BCI to assist a hemiplegic patient in regaining motor function [4] - Chengyi Tong is focusing on non-invasive BCI technologies while also preparing for potential invasive applications [4] - Entropy Technology has launched a non-invasive BCI product aimed at enhancing focus among youth, utilizing scalp electrodes and flexible sensors [4]

每周日至每周四推送股市重大公告！内容包含"停复牌、增减持、投资中标、收购、业绩、解禁、高送 转"等一系列个股利好利空公告，其中重要公告均以红色标注，帮助投资者提前寻找到投资热点，防范 各类黑天鹅事件，并且有充足的时间进行分辨和寻找合适的上市公司。 ①稳定币+区块链+移动支付+国企改革！这家公司部分技术可应用于稳定币领域；②军工信息化+算力租 赁+国产芯片+区块链+无人机+华为！这家公司多年来为国防军工提供定制和配套信息化和智能化相关嵌 入式产品与服务；③脑机接口+人形机器人+无人驾驶+多模态AI！公司获得脑机接口数百万元的订单，签 订人形机器人产品销售框架合同。 前言 ...

Company Announcements - Jihua Group's existing product system does not involve brain-computer interface related fields [1] - Prit's plan to invest 1 billion yuan to build a plastic modification materials headquarters and R&D manufacturing base in South China [1][2] - Lian De Equipment won a contract worth 157 million yuan for BOE's 8.6 generation AMOLED production line project [1][2] - Jiadu Technology plans to issue shares (H-shares) overseas and list on the Hong Kong Stock Exchange [1][2] - Longdi Group intends to acquire no more than 20.1667% equity in Jujia Technology [1][4] - New Zhonggang plans to repurchase shares worth 40 million to 80 million yuan [1][4] - Xiaogoods City expects a net profit increase of 12.57% to 17.40% in the first half of the year [1][4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials through block trading [1][4] - Lihua Co., Ltd. intends to reduce its holdings by no more than 3.00% [1][4] - Zhimin Da plans to raise no more than 213 million yuan through a private placement [1][5] - Xiangtong Co. plans to issue corporate bonds not exceeding 4 billion yuan [1][5] Performance Forecasts - Hanyu Pharmaceutical expects a half-year profit of 142 million to 162 million yuan, turning a profit compared to the previous year [4] - Taotao Automotive anticipates a net profit increase of 70.34% to 97.81% in the first half of the year [4] - Weichai Heavy Machinery expects a net profit increase of 40% to 60% in the first half of the year [4] Shareholding Changes - Lihua Co., Ltd.'s actual controller Cheng Lili and his concerted actors plan to reduce their holdings by no more than 3.00% [4] - He Shi Eye Hospital's Advanced Manufacturing Fund plans to reduce its holdings by no more than 2% [4] - Haitan Ruisheng's shareholder He Lin and his concerted actors plan to reduce their holdings by no more than 2.9463% [4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials [4] Other Announcements - Zhimin Da plans to raise no more than 213 million yuan through a private placement [5] - Yuyuan Co. plans to issue corporate bonds not exceeding 40 billion yuan [5] - Jinhongshun has terminated the planning of a major asset restructuring [5]